[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07717918":3,"trial-entities:NCT07717918":79,"trial-summary:NCT07717918":83},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":21,"primary_purpose":22,"phases":23,"enrollment_info":25,"interventions":28,"primary_outcomes":37,"secondary_outcomes":42,"sex":43,"minimum_age":44,"maximum_age":45,"healthy_volunteers":46,"eligibility_criteria":47,"std_ages":57,"locations":60,"central_contacts":70,"overall_officials":76,"references":77,"see_also_links":78},"NCT07717918","BL-RX01-BL1332-1102","A Study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Trial Participants","A Phase 1B Study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Subjects","RECRUITING","2026-08","2026-07","2026-07-21","2026-07-06","Bausch & Lomb Incorporated","INDUSTRY",false,"Single center, double-masked study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Subjects",null,[19],"Healthy",[],"INTERVENTIONAL","TREATMENT",[24],"PHASE1",{"count":26,"type":27},28,"ESTIMATED",[29,34],{"type":30,"name":31,"description":32,"armGroupLabels":33},"DRUG","BL1332 eye drops","Taken 1 time",[31],{"type":30,"name":35,"description":32,"armGroupLabels":36},"BL1332 Placebo eye drops",[35],[38],{"measure":39,"description":40,"timeFrame":41},"Ocular pain severity assessed by numeric pain rating scale (NPRS)","NPRS scale 0 to 10, with higher score reflecting worse pain","Assessed 5 seconds post-capsaicin dose",[],"ALL","18 Years","65 Years",true,{"inclusion":48,"exclusion":52,"raw_text":56},[49,50,51],"Male or female ≥ 18 to ≤ 65 years of age.","In good health, as assessed at Screening by the Investigator from past medical history, physical examination (abbreviated), and laboratory tests.","Does not wear contact lenses, or is willing to refrain from wearing contact lenses for the duration of the study.",[53,54,55],"Women of childbearing potential or non-vasectomized males with partners of childbearing potential are not eligible unless they are using an effective method of contraception and agree to use an effective method of contraception until at least 30 days after study treatment.","Any medical condition (systemic or ophthalmic) that may, in the opinion of the Investigator, preclude the safe administration of IP, safe participation in this study, or confound the assessment of safety or efficacy.","Unwilling or unable to comply with the study protocol.","Inclusion Criteria:\n\n* Male or female ≥ 18 to ≤ 65 years of age.\n* In good health, as assessed at Screening by the Investigator from past medical history, physical examination (abbreviated), and laboratory tests.\n* Does not wear contact lenses, or is willing to refrain from wearing contact lenses for the duration of the study.\n\nExclusion Criteria:\n\n* Women of childbearing potential or non-vasectomized males with partners of childbearing potential are not eligible unless they are using an effective method of contraception and agree to use an effective method of contraception until at least 30 days after study treatment.\n* Any medical condition (systemic or ophthalmic) that may, in the opinion of the Investigator, preclude the safe administration of IP, safe participation in this study, or confound the assessment of safety or efficacy.\n* Unwilling or unable to comply with the study protocol.",[58,59],"ADULT","OLDER_ADULT",[61],{"facility":62,"status":8,"city":63,"state":64,"zip":65,"country":66,"geoPoint":67},"Site 101","Newport Beach","California","92663","United States",{"lat":68,"lon":69},33.61891,-117.92895,[71],{"name":72,"role":73,"phone":74,"email":75},"Celia Busby","CONTACT","9453277624","celia.busby@bausch.com",[],[],[],{"nct_id":4,"conditions":80,"biomarkers":82},[81],"Healthy Volunteers",[],{"nct_id":4,"found":46,"summary":84,"prompt_version":94},{"design":85,"status":86,"heading":87,"summary":88,"follow_up":89,"word_count":90,"commitments":91,"compensation":92,"drugs_mentioned":93},"This is a single-center, double-masked study, meaning neither you nor the study team will know if you receive BL1332 or a placebo. It plans to enroll 28 healthy participants.","completed","Study of BL1332 for Capsaicin-Induced Eye Pain","This study is testing BL1332 eye drops to see if they can reduce eye pain caused by capsaicin (the active ingredient in chili peppers). You might be able to join if you are a healthy adult between 18 and 65 years old and do not wear contact lenses, or are willing to stop wearing them for the study. The researchers will measure your eye pain using a numeric pain rating scale (NPRS) just 5 seconds after capsaicin is given to see if BL1332 helps. We don't have information on the current recruitment status for this study.","Your pain will be assessed 5 seconds after a capsaicin dose. Further follow-up is not specified.",96,"You would receive BL1332 eye drops or placebo eye drops one time. Your eye pain would be assessed 5 seconds after a capsaicin dose.","Not stated in the trial record.",[31],"v2"]